Power Law company profile

BeOne Medicines

Biotech & Life Sciences · Dongcheng District, China · Founded 2010 · IPO 2016 Decacorn

Innovative oncology therapeutics for global cancer care accessibility, formerly BeiGene

Valuation

$29B

Market cap · 2026

Revenue

$5.34B

Latest reported FY

EBITDA

$955M

Latest reported FY

Featured in Decacorn$10B+ valuation tier · Power Law dataset 2026 $10B+ revenueThoroughbred · Power Law outcome

Investors

3 investors on BeOne Medicines's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 2 investors entered at this stage

Hillhouse Capital

CITIC Capital

Series B+ 1 investor entered at this stage

Rock Springs Capital

Global footprint

Where BeOne Medicines has talent and traffic

AI talent share

0.5% of workforce is AI talent
(11 of 2,163 staff)

Core AI20.09%

Other AI90.42%

Non-AI workforce2,15299.49%

Workforce by country

41 countries with
team presence

🇨🇳 China36.1%

🇺🇸 United States31.9%

🇦🇺 Australia6%

🇨🇭 Switzerland4.5%

🇫🇷 France2.4%

Top 5 of 41 shown

Web traffic by country

56K monthly visits
across markets

🇺🇸 United States42.1%

🇨🇭 Switzerland15.4%

🇬🇧 United Kingdom12.1%

🇮🇳 India4.1%

🇸🇬 Singapore2.7%

Top 5 markets shown

Patent intelligence

$250M patent portfolio · 425 active families

Estimated portfolio value

$250M

0.87% of market cap · 3.1× smaller than top peer BioNTech ($780M)

425 active patent families

Where BeOne Medicines innovates Molecular biologyDiseaseCarcinosisAntiendomysial antibodiesAntigen Binding Fragment

Where BeOne Medicines concentrates vs peers

Each axis is a top-10 topic across BeOne Medicines and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Capital deployed

BeOne Medicines's 5 investments and acquisitions.

Every disclosed deal where BeOne Medicines appeared as a backer or acquirer, 2021–2026. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

5 deals across BeOne Medicines's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount

By stageCount

By periodCount

01 · Deployment strategy vs peers

Where BeOne Medicines deploys vs peers

Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.

Compare against

02 · Portfolio market map

BeOne Medicines's portfolio, mapped.

Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

Stage

Period

5 of 5 deals

Market sentiment

What the market is saying about BeOne Medicines

An AI-synthesized read of the highest-engagement posts about BeOne Medicines on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See BeOne Medicines on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles